We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Can Cancer Cells Be Reprogrammed Back to Normality?

By LabMedica International staff writers
Posted on 11 Nov 2008
Print article
A team of cancer researchers has published a report suggesting a novel approach to cancer therapy: instead of killing cancer cells, why not reprogram them to become normal again?

Investigators at Syracuse University (NY, USA) worked on leukemia, the form of cancer caused by the abnormal production of white blood cells in the bone marrow. They focused on the Mixed Lineage Leukemia protein-1 (MLL1), which is one of the proteins that regulate the way DNA is packaged when white blood cells are formed. MLL1 belongs to the SET1 family of histone H3 lysine 4 methyltransferases. In normal cells, the MLL protein, which contains 3,969 amino acids, combines with three other proteins, WD-repeat protein-5 (WDR5), retinoblastoma binding protein-5 (RbBP5), and the Absent small homeotic-2-like protein (Ash2L) to create a molecular switch that controls DNA packaging.

The current paper published in the October 1, 2008, online edition of the Journal of Biological Chemistry (JBC), revealed that WDR5 preferentially recognized a previously unidentified and conserved arginine containing motif called the "Win” or WDR5 interaction motif, which is located in the N-SET region of MLL1 and other SET1 family members. The Win motif comprised six amino acids and was responsible for assembling the MLL1 molecular switch in normal cells. Treatment of cells with a synthetic version of this peptide disrupted the MLL1 molecular switch and prevented white blood cell formation.

"We believe our discovery is just the tip of the iceberg,” said senior author Dr. Michael Cosgrove, assistant professor of biology at Syracuse University. "Our hope is that from the knowledge we have gained in understanding how these proteins work in normal cells, we will be able to find new ways to treat all types of leukemia. We also think the discoveries will have broad implications in treating other types of cancer.”

The investigators speculated that the MLL1 peptide might help to reprogram DNA packaging in leukemia cells and trigger the conversion of cancer cells back into normal cells. "Reprogramming the way DNA is packaged in cancerous cells is a new idea that has the potential to lead to better treatments with fewer side effects,” said Dr. Cosgrove. "This last year has been fantastic. We have been learning something new about these proteins almost on a daily basis. Our hope is that as we continue to understand how these DNA packaging proteins work, we will find new ways to treat all types of leukemia as well as other diseases.”

Related Links:
Syracuse University

Gold Member
Veterinary Hematology Analyzer
Exigo H400
Verification Panels for Assay Development & QC
Seroconversion Panels
New
HIV-1 Test
HIV-1 Real Time RT-PCR Kit
New
Silver Member
Verification Panels for Assay Development & QC
Seroconversion Panels

Print article

Channels

Immunology

view channel
Image: The findings were based on patients from the ADAURA clinical trial of the targeted therapy osimertinib for patients with NSCLC with EGFR-activated mutations (Photo courtesy of YSM Multimedia Team)

Post-Treatment Blood Test Could Inform Future Cancer Therapy Decisions

In the ongoing advancement of personalized medicine, a new study has provided evidence supporting the use of a tool that detects cancer-derived molecules in the blood of lung cancer patients years after... Read more

Microbiology

view channel
Image: Schematic representation illustrating the key findings of the study (Photo courtesy of UNIST)

Breakthrough Diagnostic Technology Identifies Bacterial Infections with Almost 100% Accuracy within Three Hours

Rapid and precise identification of pathogenic microbes in patient samples is essential for the effective treatment of acute infectious diseases, such as sepsis. The fluorescence in situ hybridization... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.